1 story in the last 7 days
The latest autoimmune news, distilled by AI into sharp ~100-word summaries. ByteBrief tracks autoimmune across dozens of tech sources and brings you only what matters, updated hourly. Tap any story for the full brief, or open the original source.
Cabaletta Bio delivered positive clinical data from the first four patients in the lowest dose cohort of PC-free rese-cel, an autologous CAR T therapy for autoimmune diseases. 50% of patients showed drug-free responses for six months. The company signed a long-term commercial supply agreement and plans to advance rese-cel toward BLA submission for a commercial launch.
Summaries by ByteBrief